Allgens(SH:688613) Xin Lang Cai Jing·2026-01-28 09:28Core Viewpoint - The company, Aojing Medical (688613.SH), anticipates a significant increase in revenue and a turnaround in profitability for the year 2025, driven by strategic market initiatives and enhanced production capabilities [1] Financial Projections - The company expects to achieve an operating revenue of approximately 223.51 million yuan in 2025, representing an increase of about 17.47 million yuan or 8.48% compared to the previous year [1] - The projected net profit attributable to the parent company is around 13.53 million yuan, an increase of approximately 26.19 million yuan, indicating a turnaround from a loss to profitability [1] - The net profit attributable to the parent company, excluding non-recurring gains and losses, is expected to be around -514,700 yuan, reflecting an increase of approximately 2.78 million yuan compared to the previous year [1] Market Strategy and Growth - The orthopedic artificial bone procurement has provided the company with opportunities for continued clinical usage growth and market share expansion [1] - The company is enhancing its production assurance system to meet the increased demand resulting from the procurement [1] - The marketing strategy focuses on deepening regional market strategies through refined management and targeted marketing efforts, continuously expanding the sales network [1] - The company has demonstrated steady revenue growth throughout the year, further solidifying its leading position in the niche market [1]